GeneralConnection.com ➔ Dictionary
Dictionary Search

mesoblast

Synonyms

Noun

1. mesoderm

2. germ layer

Usage
Why Mesoblast Limited (MESO) is One of the Best Low Priced Biotech Stocks to Invest in - Yahoo Finance
FDA clears trial testing Mesoblast cell therapy in kids with DMD - Muscular Dystrophy News
Mesoblast Limited (MESO) Presents at ASX CEO Connect June 2026 - Slideshow (NASDAQ:MESO) 2026-06-04 - Seeking Alpha
Hope for Back Pain: Mesoblast’s Phase 3 Trial Fully Enrolled - The Clinical Trial Vanguard
Latham & Watkins Advises Leading Stem Cell Biotech Mesoblast on Refinancing of Up to US$125 Million - Latham & Watkins LLP
MESO Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Assessing Mesoblast’s Valuation After Recent Share Price Weakness And Conflicting Growth Signals - Yahoo Finance
Mesoblast Limited: A Risk/Reward Story (NASDAQ:MESO) - Seeking Alpha
Mesoblast Limited (MESO), One of the Best Long-Term ASX Stocks To Buy Right Now; See Why - Yahoo Finance
Gregory George Adds To Mesoblast Position With Multi-Market Share Purchases - Yahoo Finance
Mesoblast (ASX:MSB) Is Down 11.0% After FDA Clears Registrational DMD Trial For Ryoncil - Has The Bull Case Changed? - Yahoo Finance
How Completion Of RMAT Phase 3 Enrollment At Mesoblast (ASX:MSB) Has Changed Its Investment Story - Yahoo Finance
Is Mesoblast (ASX:MSB) Price Swings Creating A Possible Valuation Opportunity? - Yahoo Finance
Mesoblast (ASX:MSB) Is Down 7.1% After Issuing First Ryoncil 2026 Revenue Guidance – Has The Bull Case Changed? - Yahoo Finance
Mesoblast (ASX:MSB) Valuation Check as Board Revamp Supports Commercial Expansion Strategy - Yahoo Finance
Mesoblast Ltd (MESO): Secure Exclusive Rights to a Vital Platform - Yahoo Finance
How Investors Are Reacting To Mesoblast (ASX:MSB) Remestemcel-L’s Remission Edge And FDA-Backed Niche Leadership - Yahoo Finance
Mesoblast (ASX:MSB): Reassessing Valuation After Recent Share Price Rebound and Long-Term Return Surge - Yahoo Finance
Mesoblast H1 Earnings Call Highlights - Yahoo Finance
Mesoblast Limited (ASX:MSB): Are Analysts Optimistic? - Yahoo Finance
Mesoblast gains on licensing deal for CAR technology platform - MSN
Mesoblast drops after Ryoncil sales data for March quarter - Seeking Alpha
Mesoblast: Real-World Data Validates The Bull Case For Ryoncil (NASDAQ:MESO) - Seeking Alpha
Mesoblast fills Phase 3 study of non-opioid shot for back pain - Stock Titan
Mesoblast (NASDAQ: MESO) completes enrollment in pivotal Phase 3 chronic low back pain study - Stock Titan
Mesoblast acquires CAR technology license from Mayo Clinic - Investing.com
Gregory George Bought 40% More Shares In Mesoblast - Yahoo Finance
Why Mesoblast's Move Into DMD Warrants A Speculative Buy (Upgrade) (NASDAQ:MESO) - Seeking Alpha
FDA clears Mesoblast DMD trial for Ryoncil in children - Investing.com
Assessing Mesoblast (ASX:MSB) Valuation After Phase 3 Recruitment Milestone For Rexlemestrocel L - simplywall.st
Mesoblast Limited (MESO) Stock Analysis: Exploring A 109.83% Potential Upside - DirectorsTalk Interviews
Mesoblast (ASX:MSB): Assessing Valuation Following Recent Share Price Surge - Yahoo Finance
Mesoblast Stock (MESO) Opinions on FDA IND Clearance for Ryoncil in DMD | MESO Stock News - Quiver Quantitative
Mesoblast says Ryoncil is nearing $100M as new trials move ahead - Stock Titan
CAR platform expands Mesoblast (MEOBF) cell therapy pipeline reach - Stock Titan
FDA Confirms Rexlemestrocel-L Efficacy for Back Pain Relief - The Clinical Trial Vanguard
Mesoblast (MESO) Sees Revenue Surge and Secures $125M Loan - GuruFocus
Mesoblast announces board leadership changes as company evolves - Investing.com
Jefferies upgrades Mesoblast stock to Buy on strong Ryoncil sales - Investing.com
Mesoblast earnings beat by $0.02, revenue fell short of estimates - Investing.com
Gregory George beneficial owner at Mesoblast (OTC: MEOBF) with 22.36% stake - Stock Titan
Mesoblast invests in smarter cell therapies with new CAR tech deal - Longevity.Technology
Mesoblast Full Year 2025 Earnings: Misses Expectations - Yahoo Finance
Mesoblast’s Ryoncil Gains Permanent CMS J-Code for Billing and Reimbursement - Yahoo Finance
Mesoblast hits enrollment target in pivotal trial offering a non-opioid approach to chronic low back pain - Biotech Dispatch
Cancer trial veteran Teresa Montagut to steer Mesoblast’s cell therapy push - Stock Titan
Mesoblast gains as FDA clears study to test Ryoncil in Duchenne - Seeking Alpha
Mesoblast child graft-versus-host therapy shows 84% survival - Stock Titan
Mesoblast Climbs (ASX:MSB) as Biotech Buyers Return to the Health Sector - Kalkine
Mesoblast completes enrollment in back pain therapy trial - Investing.com
Mesoblast (MESO) Secures Global License for Advanced CAR Technol - GuruFocus
Earnings call transcript: Mesoblast’s strong Q1 2026 performance boosts outlook - Investing.com
Mesoblast reports $US35.1m in gross revenue from sales of its cell therapy Ryoncil - Proactive financial news
Mesoblast to Meet FDA on Rexlemestrocel-L for Opioid Use - The Clinical Trial Vanguard
Mesoblast Limited (MESO) Stock Report: Exploring A 91.36% Potential Upside - DirectorsTalk Interviews
Mesoblast Advances CAR Cell Therapy Platform And Late Stage Pain Trial - simplywall.st
Mesoblast climbs after inking an exclusive global licence from Mayo Clinic - Capital Brief
Is Mesoblast (ASX:MSB) Offering Value After Recent Share Price Declines? - simplywall.st
Mesoblast Says Nearly $100 Million in Revenue Generated During First Year of Ryoncil Launch; Shares Fall 5% - marketscreener.com
FDA clears Mesoblast to advance Ryoncil into late stage trial for Duchenne Muscular Dystrophy - Biotech Dispatch
Mesoblast Limited (MESO) Stock Analysis: Unlocking 71.87% Potential Upside - DirectorsTalk Interviews
Mesoblast's Fiscal 2026 Net Revenue Projected to be Up to $120 Million, Jefferies Says - marketscreener.com
FDA clears Mesoblast for pivotal DMD clinical trial - grafa.com
Mesoblast H1 FY26 slides: first approved MSC product hits $49M - Investing.com
Mesoblast Reports Ryoncil® Net Revenues of US$30.3m and Improved Net Operating Cash Spend for the Quarter to US$4.1 Million - The Manila Times
Is Completing Phase 3 Enrollment For Rexlemestrocel-L Reshaping The Investment Case For Mesoblast (ASX:MSB)? - simplywall.st
Mesoblast (MESO) Reports Significant Miss in 1H Earnings - GuruFocus
Has Mesoblast’s Surging Share Price Left Its Future Growth Prospects Underappreciated? - webull.com
Cynata Therapeutics' Drug Candidate's Potential Reinforced by Mesoblast Results, Says Euroz Hartleys - Moomoo
Mesoblast to meet with U.S. FDA over potential non-opioid treatment for chronic back pain - Biotech Dispatch
Mesoblast H1 2026 Loss Of US$94.4 Million Tests Bullish Profitability Narratives - simplywall.st
US regulator signals path forward for Mesoblast’s cell therapy - Biotech Dispatch
Mesoblast: Back Pain And Heart Failure Remain Option Value, Not Base Case - Seeking Alpha
Mesoblast Says Ryoncil's Net Revenue For Quarter Increases To US$30.3M - TradingView
Bell Potter Maintains MESOBLAST LTD(MEOBF.US) With Buy Rating, Raises Target Price to $3.1 - Moomoo
Mesoblast to launch pivotal adult trial for cell therapy in severe steroid-refractory GVHD - Biotech Dispatch
Mesoblast reports $30.3 million in Ryoncil quarterly sales - grafa.com
Mesoblast to meet FDA on opioid reduction data from Rexlemestrocel-L Phase 3 trial - Proactive financial news
How Mesoblast’s founder proved the shorters wrong - AFR
A Spark Becomes a Surge: How Ryoncil Reignited MSC Development - BioInformant
Does Mesoblast (ASX:MSB) Deserve a Spot on Your Healthcare Watchlist? - Kalkine
Buy, hold, sell: Mesoblast, Mineral Resources, and Woolworths shares - MSN
ASX opens lower as CBA slides; Web Travel Group and Mesoblast surge - Capital Brief
Mesoblast Receives IND Clearance From FDA to Directly Proceed to Registrational Trial for Approval of Ryoncil in Duchenne Muscular Dystrophy - CORRECTION - Bitget
Mesoblast Acquires Chimeric Antigen Receptor (CAR) Platform Technology for Precision-Enhanced Cell Products - The Manila Times
Mesoblast shares hit five-year high as Ryoncil sales up 60pc - Business News Australia
Mesoblast FDA feedback: rexlemestrocel-L BLA path confirmed - grafa.com
Mesoblast Touts High Survival Rates For FDA-Approved Cell Therapy - Bitget
Mesoblast acquires Mayo Clinic CAR-MSC technology licence - grafa.com
Mesoblast stock reaches 52-week high at 21.05 USD By Investing.com - Investing.com South Africa
"To me, it was a miracle": Stem cell therapy offers healing for Oklahoma sisters back pain - KOKH
Mesoblast (ASX:MSB; Nasdaq:MESO) Sets Stage for R&D Day as Ryoncil® Gains Commercial Traction - Kalkine Media
Mesoblast appoints Chief Financial Officer as it evolves into fully integrated commercial organisation - Biotech Dispatch
Health Check: ‘We’ve only just started’, Mesoblast tells investors at inaugural show-and-tell - Stockhead
Mesoblast hits US$100M revenue milestone with Ryoncil - grafa.com
Dr Boreham’s Crucible: The long grind finally pays off for Mesoblast - Stockhead
Mesoblast Shares Rise After Ryoncil Sales Jump in Q4 - marketscreener.com
Mesoblast Limited (MESO) Stock Analysis: A Biotech with 149% Upside Potential Amidst Rapid Revenue Growth - DirectorsTalk Interviews
Why are Mesoblast shares jumping 8% today? - MSN
ASX-shares of Mesoblast rise on strong Ryoncil sales - TradingView
Foreign Language Equivalents
Foreign Language Equivalents of 'mesoblast'
Language Equivalent   Language Equivalent
French    Spanish
Misspellings - Typos
mesobladt,   meoblast,   mesoblst,   mesoblats,   mesoblas,   mseoblast,   mesoblaast,   mesiblast,   meaoblast,   mesobalst,   mwsoblast,   ,esoblast,   mesobllast,   mesooblast,   mesolbast,   mesoblasy,   mesolast,   meesoblast,   mrsoblast,   mesobast,   mesoblsat,   mmesoblast,   emsoblast,   nesoblast,   mesoblaat,   mesob;ast,   mespblast,   esoblast,   mesoblat,   mesoblasst,   mesobblast,   meosblast,   mesonlast,   messoblast,   mesobkast,   mesbolast,   msoblast,   mesovlast,   mesoblastt,   medoblast,   mesblast,   mesoblsst,   mesoblasr
Words Starting with Letter - 'A'
a a battery a billion
a bit a bit much a capella singing
a cappella singing a couple of a few
a fortiori a good deal a great deal
a horizon a hundred a hundred and one
a hundred thousand a hundred times a kempis
a la carte a la mode a level
a little a lot a million
Go to Page 1              Go to Page 2 »   
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z